Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Similar documents
Urinary Bladder, Ureter, and Renal Pelvis

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Protocol applies to melanoma of cutaneous surfaces only.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

CPC on Cervical Pathology

Retinoblastoma. Protocol applies to retinoblastoma only.

Testis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.

Uveal Melanoma. Protocol applies to malignant melanoma of the uvea.

Endometrium. Protocol applies to all carcinomas of the endometrium. Procedures Cytology (No Accompanying Checklist) Biopsy Curettage Hysterectomy

Protocol applies to specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood.

Cervical Cancer: 2018 FIGO Staging

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

Definition of Synoptic Reporting

Staging and Treatment Update for Gynecologic Malignancies

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

Cervical cancer presentation

Coversheet for Network Site Specific Group Agreed Documentation

This protocol is intended to assist pathologists in providing

Urinary Bladder, Ureter, and Renal Pelvis

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

Carcinoma of the Urinary Bladder Histopathology

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

VULVAR CARCINOMA. Page 1 of 5

Protocol for the Examination of Specimens From Patients With Carcinoma of the Uterine Cervix

Jacqui Morgan March 6, 2019

Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva Malignant melanoma sho

Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Vagina

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Fallopian Tube. Protocol applies to all invasive carcinomas of the fallopian tube.

What is endometrial cancer?

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

Uterus Malignancies /5/15

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous

Uterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

Gynecologic Oncology Overview Staging updates and Soap Box Issues

Algorithms for management of Cervical cancer

Carcinoma of the Cervix Histopathology Reporting Guide

CARCINOMA CERVIX. Dr. PREETHI REDDY. B. M S OBG II yr POST GRADUATE.

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging

Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Uterine Cervix

NAACCR Webinar Series /7/17

Chapter 8 Adenocarcinoma

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Uterine Cervix

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

S1.04 Principal clinician. G1.01 Comments. G2.01 *Specimen dimensions (prostate) S2.02 *Seminal vesicles

Carcinoma of the Renal Pelvis and Ureter Histopathology

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA

Gastric Cancer Histopathology Reporting Proforma

Computed tomography for evaluation of cervical carcinoma: Our experience in a tertiary care hospital.

Protocol for the Examination of Specimens From Patients With Carcinoma of the Vagina

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

George Cernile Artificial Intelligence in Medicine Toronto, ON. Carol L. Kosary National Cancer Institute Rockville, MD

The pathology of bladder cancer

UICC TNM 8 th Edition Errata

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do?

Extrahepatic Bile Ducts

Most common cancer Africans & Asians more prone because of poor socioeconomic condition Drastic decline in west as more detection of preinvasive

Protocol for the Examination of Specimens From Patients With Primary Malignant Tumors of the Heart

Estimated New Cancers Cases 2003

Case 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

of surgical management of early invasive cervical cancer chapter Diagnosis and staging Wertheim described the principles

Protocol for the Examination of Specimens from Patients with Carcinoma of the Vulva

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

Dr. Homer Bloomfield Cancer Society of the Bahamas

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53

Cervical Cancer Early Detection, Diagnosis, and Staging

MRI for cervical and endometrial cancers. Dr Robert Bleehen Consultant Radiologist Cardiff & Vale UHB

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Current staging of endometrial carcinoma with MR imaging

ECC or Margins Positive?

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.

MR imaging of FIGO stage I uterine cervical cancer: The diagnostic impact of 3T-MRI

Vaginal intraepithelial neoplasia

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

Vaginal Cancer Early Detection, Diagnosis, and Staging

S1.04 PRINCIPAL CLINICIAN G1.01 COMMENTS S2.01 SPECIMEN LABELLED AS G2.01 *SPECIMEN DIMENSIONS (PROSTATE) S2.03 *SEMINAL VESICLES

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

Colorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY

A215- Urinary bladder cancer tissues

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

Endometrial Cancer. Incidence. Types 3/25/2019

Interactive Staging Bee

H&E, IHC anti- Cytokeratin

The new FIGO classification in endometrial carcinoma

Janjira Petsuksiri, M.D

Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University

Transcription:

Uterine Cervix Protocol applies to all invasive carcinomas of the cervix. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report Procedures Cytology (No Accompanying Checklist) Incisional/Punch Biopsy (No Accompanying Checklist) Excisional/Cone Biopsy Hysterectomy Pelvic Exenteration Author Philip A. Branton, MD Department of Pathology, Inova Fairfax Hospital, Falls Church, Virginia For the Members of the Cancer Committee, College of American Pathologists Previous contributors: Robert J. Kurman, MD; Mahul B. Amin, MD

Gynecologic Uterine Cervix CAP Approved 2005. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College. The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the Surgical Pathology Cancer Case Summary (Checklist) portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice. The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document. 2

CAP Approved Gynecologic Uterine Cervix Summary of Changes to Checklist(s) Protocol revision date: January 2005 No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision. 3

Gynecologic Uterine Cervix CAP Approved Surgical Pathology Cancer Case Summary (Checklist) UTERINE CERVIX: Cone Biopsy Patient name: Surgical pathology number: Note: Check 1 response unless otherwise indicated. Protocol revision date: January 2005 Applies to invasive carcinomas only Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report MACROSCOPIC Tumor Site Right superior quadrant (12 to 3 o clock) Right inferior quadrant (3 to 6 o clock) Left inferior quadrant (6 to 9 o clock) Left superior quadrant (9 to 12 o clock) Not specified MICROSCOPIC *Tumor Size *Dimensions: x x mm * Cannot be determined (see Comment) Note: all dimensions important; see definition for microinvasive carcinoma under T1a1/IA1 Histologic Type (check all that apply) Squamous cell carcinoma * Keratinizing * Nonkeratinizing * Other (specify): Adenocarcinoma * Mucinous * Endocervical type * Intestinal type * Endometrioid * Clear cell * Other (specify): Other (specify): Carcinoma, type cannot be determined 4

CAP Approved Gynecologic Uterine Cervix Histologic Grade Not applicable GX: Cannot be assessed G1: Well differentiated G2: Moderately differentiated G3: Poorly differentiated G4: Undifferentiated Stromal Invasion Depth: mm Horizontal extent: mm Extent cannot be assessed Margins (check all that apply) Margins cannot be assessed (eg, obscuring electrocautery artifact) Endocervical Margin Uninvolved by invasive carcinoma *Distance of invasive carcinoma from margin: mm Involved by invasive carcinoma * Focal * Diffuse * Uninvolved by intraepithelial neoplasia * Involved by intraepithelial neoplasia *Specify grade: Exocervical Margin Uninvolved by invasive carcinoma *Distance of invasive carcinoma from margin: mm Involved by invasive carcinoma * Focal * Diffuse * Uninvolved by intraepithelial neoplasia * Involved by intraepithelial neoplasia *Specify grade: Deep Margin Uninvolved by invasive carcinoma *Distance of invasive carcinoma from margin: mm Involved by invasive carcinoma * Uninvolved by intraepithelial neoplasia * Involved by intraepithelial neoplasia *Specify grade: 5

Gynecologic Uterine Cervix CAP Approved *Additional Pathologic Findings (check all that apply) * None identified * Koilocytosis * Inflammation * Other (specify): *Comment(s) 6

CAP Approved Gynecologic Uterine Cervix Surgical Pathology Cancer Case Summary (Checklist) Protocol revision date: January 2005 Applies to invasive carcinomas only Based on AJCC/UICC TNM, 6 th edition and FIGO 2001 Annual Report UTERINE CERVIX: Colpectomy, Hysterectomy, Pelvic Exenteration Patient name: Surgical pathology number: Note: Check 1 response unless otherwise indicated. MACROSCOPIC Specimen Type Colpectomy Hysterectomy Radical hysterectomy Pelvic exenteration Not specified Tumor Site (check all that apply) Right superior quadrant Right inferior quadrant Left superior quadrant Left inferior quadrant Not specified Tumor Size Greatest dimension: cm *Additional dimensions: x cm Cannot be determined (see Comment) 7

Gynecologic Uterine Cervix CAP Approved Other Organs Present None Right ovary Left ovary Right fallopian tube Left fallopian tube Uterine corpus Vagina Urinary bladder Rectum Other(s) (specify): MICROSCOPIC Histologic Type (check all that apply) Squamous cell carcinoma * Keratinizing * Nonkeratinizing * Other (specify): Adenocarcinoma * Mucinous * Endocervical type * Intestinal type * Endometrioid * Clear cell * Other (specify): Other (specify): Carcinoma, type cannot be determined Histologic Grade Not applicable GX: Cannot be assessed G1: Well differentiated G2: Moderately differentiated G3: Poorly differentiated G4: Undifferentiated 8

CAP Approved Gynecologic Uterine Cervix Pathologic Staging (ptnm [FIGO]) Primary Tumor (pt) ptx [--]: Cannot be assessed pt0 [--]: No evidence of primary tumor ptis [0]: Carcinoma in situ pt1 [I]: Cervical carcinoma confined to uterus (extension to corpus should be disregarded) pt1a [IA]: Invasive carcinoma diagnosed by microscopy only. All macroscopically visible lesions (even with superficial invasion) are pt1b/1b. pt1a1 [IA1]: Stromal invasion 3.0 mm or less in depth and horizontal spread 7.0 mm or less ( microinvasive carcinoma ) pt1a2 [IA2]: Stromal invasion more than 3.0 mm but not more than 5.0 mm in depth pt1b [IB]: and horizontal spread 7.0 mm or less Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a2/IA2 pt1b1 [IB1]: Clinically visible lesion 4.0 cm or less in greatest dimension pt1b2 [IB2]: Clinically visible lesion more than 4.0 cm in greatest dimension pt2 [II]: Tumor invades beyond the uterus but not to pelvic wall or to lower third of vagina pt2a [IIA]: Tumor without parametrial invasion pt2b [IIB]: Tumor with parametrial invasion pt3 [III]: Tumor extends to the pelvic wall and/or involves the lower third of the vagina and/or causes hydronephrosis or nonfunctioning kidney pt3a [IIIA]: Tumor involves lower third of vagina, but not pelvic wall pt3b [IIIB]: Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney pt4 [IVA]: pm1[ivb]: Tumor invades the mucosa of bladder or rectum and/or extends beyond true pelvis (bullous edema is not sufficient evidence to classify a tumor as pt4) Distant metastasis Regional Lymph Nodes (pn) pnx: Cannot be assessed pn0: No regional lymph node metastasis pn1: Regional lymph node metastasis Specify: Number examined: Number involved: Distant Metastasis (pm) pmx: Cannot be assessed pm1 [IVB]: Distant metastasis *Specify site(s), if known: 9

Gynecologic Uterine Cervix CAP Approved Margins (check all that apply) Cannot be assessed Margins uninvolved by invasive carcinoma Distance of invasive carcinoma from closest margin: mm Specify margin, if possible: Carcinoma in situ absent at distal margin Carcinoma in situ present at distal margin Margin(s) involved by invasive carcinoma Specify location(s), if possible: Not applicable *Venous/Lymphatic (Large/Small Vessel) Invasion (V/L) * Absent * Present * Indeterminate *Additional Pathologic Findings (check all that apply) * None identified * Intraepithelial neoplasia (specify type and grade): * Other (specify): *Comment(s) 10